Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
We studied 21 women with postmenopausal osteoporosis, treated with salmon calcitonin nasal spray (100 IU/daily) and calcium (1 g/daily) for six months. Bone mineral content (BMC), measured before and at the end of therapy with lumbar dual photon absorptiometry, showed a significant increase (p < 0.01). At the end of the study, there was also a clear improvement of osteoporotic pain. Among biochemical markers of bone turnover, there was a significant (p < 0.01) reduction of urinary excretion of hydroxyproline. No side effect was registered and all patients had a good compliance to therapy.
Tolino
A
A
Institute of Obstetrics, Gynecology and Physiopathology of Human Reproduction, Faculty of Medicine and Surgery, University of Naples, Italy.
Romano
L
L
Ronsini
S
S
Riccio
S
S
Montemagno
U
U
D015502:Absorptiometry, Photon; D000280:Administration, Inhalation; D000336:Aerosols; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D010146:Pain / Q000517:prevention & control
D000336:Aerosols; C028815:salmon calcitonin; D002116:Calcitonin; D006909:Hydroxyproline; D002118:Calcium